Loading company…
ValenzaBio develops antibody therapies for autoimmune and inflammatory disorders.
ValenzaBio is a privately held biopharmaceutical company founded by Patrick Crutcher and David Maizenberg and based in Maryland, US. Its antibody programs include VB119 for membranous nephropathy and VB421 for thyroid eye disease. The company raised its first funding in February 2020 and Series A funding in April 2021, when Pierre Fabre Medicament also took an equity stake.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in